Olivia Vizier

A key part of what makes Y-mAbs Therapeutics’ two-step bispecific fusion protein and radiotherapeutic effective comes down to concentration.

Big pharma and investors are piling into the precision radiation space as the next generation of increasingly potent targeted α-particle therapies promises to destroy cancerous cells with minimum damage to healthy tissues.

CAMP4 is currently working on CMP-CPS-001, a novel investigational therapy designed to address the underlying cause of UCDs by regulating genes associated with the condition. The first clinical trial of this program was initiated in March 2024 with a phase 1 single-ascending dose study in healthy volunteers. Following the completion of this trial, a multiple-ascending

Rex’s company, F2G, is in the final stages of clinical trials for an antifungal drug called olorofim. This drug prevents fungi from making pyrimidines, a type of building block for DNA and RNA. Interfering in that process prevents fungi from replicating and can kill some dangerous fungi, including Aspergillus species. If the drug is approved

Harbinger Health is advancing a blood-based screening platform initially focused on pancreatic and biliary cancers – two of the deadliest malignancies that currently lack effective screening programs and are often…

Innovation in pharma isn’t just about molecules and machinery; it’s powered by people. Visionaries, disruptors, and dedicated minds drive the next wave of medicine, transforming bold ideas into life-changing therapies for patients around the world.

In this episode of In Combination, host Tom von Gunden combines the perspectives of three executives at Revolo Biotherapeutics – CEO Woody Bryan,

MindMed recently announced that the first patient has been dosed in its phase 3 Emerge study evaluating MM120 ODT for treatment of major depressive disorder (MDD). MM120 ODT is a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD).

CAMP4 Therapeutics is targeting regulatory RNA, whose role in gene expression was first described by co-founder and MIT Professor Richard Young.

Cue applied technology it initially tested in the treatment of cancers to the development of CUE-501. The idea is to make B cells appear as if they are infected with a virus such as cytomegalovirus or SARS-CoV-2.

Here’s how real scientists are effectively preparing to battle fungus today.

CorVista is bringing AI to bear on cardiac diagnostics, helping hospitals and doctors identify who need the most care.

John Kane, MD, shared new positive phase 2 data on N-methyl amisulpride (LB-102) for the treatment of patients with acutely exacerbated schizophrenia at the 2025 Annual Congress of the Schizophrenia International Research Society.

Dr Carsten Rudolph, Cofounder and Chief Executive Officer at Ethris, said that from a partnering perspective, he observed some shifts in trends.

Many drug manufacturers, healthcare providers, and patients see the potential benefits of producing autologous therapies at the point of care (POC). However, even among its proponents, there is less agreement on the best path forward, says AltruBio CEO Judy Chou, Ph.D.

Raj shares his journey from big pharma to biotech entrepreneurship, the science behind Rectify’s groundbreaking approach to drugging membrane proteins, and how his team is tackling rare hepatobiliary diseases with small-molecule therapies.

Oncolytics Biotech has a treatment in development for breast, pancreatic, and anal cancer. Pharmaceutical Executive spoke with chief medical officer Thomas C. Heineman, MD, PhD, and vice president of business development Christophe Degois about the company’s pipeline and financial status.

Did you know that one in ten people with Type 1 Diabetes (TD1) die from hypoglycemia? Today’s guest, who has TD1, explains how he turned his passion for helping others into innovative treatments for diabetes and other chronic diseases.

This time around, we note that Sernova Biotherapeutics hired Pericles Calias as chief development officer and head of R&D. Previously, he served as interim chief development officer at Vibe Bio, in addition to doing consulting and board work.

Life Biosciences, the company co-founded by the Harvard study’s lead author Dr David Sinclair, is gearing up to launch the first ever partial epigenetic reprogramming candidate into the clinic this year.

In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering

Revolo Biotherapeutics is developing a synthetic peptide therapy that can potentially restore immune system homeostasis in EOE and other allergic diseases.

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders. Now it’s on the cusp of its first regulatory approval.

COUR Pharmaceuticals’ emerging platform reprograms the immune system to address the root causes of autoimmune diseases

With LB Pharmaceuticals, Turner “liked the fact that it’s a very focused neuropsych company; this is where we’re going. And I also liked the fact that there was a near-term catalyst with our Phase 2 clinical program.” In other words, the company had a clear strategy in place; all it needed was a leader who

Last year, Tessera Therapeutics’ CEO, Dr. Michael Severino, was my guest on Cell & Gene: The Podcast to discuss Gene Writing, the biotech’s genome

A private startup looking to bring an old schizophrenia drug class to the US has released new Phase 2 data and aims to start a …

LB Pharmaceuticals has shared top-line data from a phase 2 schizophrenia trial, touting results that offer early support for its vision and putting it on track to start a pivotal study around the end of the year.

MindMed announced the first patient had been dosed in the first-ever phase 3 trial of lysergic acid-diethylamide (LSD) for generalized anxiety disorder (GAD). MindMed is currently the furthest along in clinical trials exploring LSD as a treatment in multiple psychiatric indications, including major depressive disorder.